Korro Bio, Inc. (KRRO) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Cambridge, MA, United States. The current CEO is Ram Aiyar.
KRRO has IPO date of 2019-10-03, 112 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $128.59M.
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
